Automate Your Wheel Strategy on TEM
With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEM
- Rev/Share 6.3177
- Book/Share 2.9028
- PB 19.7364
- Debt/Equity 2.6305
- CurrentRatio 3.2755
- ROIC -0.1014
- MktCap 9903347623.0
- FreeCF/Share -1.4182
- PFCF -39.9161
- PE -49.1603
- Debt/Assets 0.5855
- DivYield 0
- ROE -0.6796
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEM | Mizuho | -- | Outperform | -- | $100 | Feb. 19, 2026 |
| Initiation | TEM | Robert W. Baird | -- | Outperform | -- | $59 | Feb. 17, 2026 |
| Resumed | TEM | Morgan Stanley | -- | Overweight | -- | $85 | Dec. 2, 2025 |
| Downgrade | TEM | TD Cowen | Buy | Hold | -- | $88 | Oct. 21, 2025 |
| Initiation | TEM | Canaccord Genuity | -- | Buy | -- | $110 | Oct. 20, 2025 |
| Initiation | TEM | H.C. Wainwright | -- | Buy | -- | $90 | Sept. 2, 2025 |
| Initiation | TEM | BTIG Research | -- | Buy | -- | $60 | April 21, 2025 |
| Downgrade | TEM | JP Morgan | Overweight | Neutral | $50 | $55 | Feb. 25, 2025 |
| Downgrade | TEM | William Blair | Outperform | Market Perform | -- | -- | Feb. 12, 2025 |
| Resumed | TEM | TD Cowen | -- | Buy | $58 | $74 | Feb. 5, 2025 |
News
Live Earnings: Will Tempus AI Surprise Wall Street Tonight?
Published: February 24, 2026 by: 24/7 Wall Street
Sentiment: Neutral
We are updating this story in real time as new information breaks. Stay on this page for the latest developments, key quotes, numbers, and market reaction as they happen.
Read More
Here's How Tempus AI Is Tapping the Imagining Space
Published: February 23, 2026 by: Zacks Investment Research
Sentiment: Positive
TEM expands into radiology via Median partnership, adding AI lung screening to Pixel as FDA clearance and past deals boost imaging push.
Read More
AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
TEM rolls out new AI tools across oncology, cardiology and mental health, accelerating its push to reshape MedTech innovation.
Read More
Is TEM Stock A Buy At $60?
Published: February 19, 2026 by: Forbes
Sentiment: Neutral
Tempus AI (NASDAQ: TEM) trades at a premium by traditional metrics, remains unprofitable on a GAAP basis, and has spent the past week benefiting from strong analyst optimism. So why might the stock still appear attractive at $60?
Read More
Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Tempus (TEM) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week's Earnings
Published: February 18, 2026 by: 24/7 Wall Street
Sentiment: Positive
Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for February 24, 2026 after market close.
Read More
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
Read More
Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel
Published: February 17, 2026 by: Zacks Investment Research
Sentiment: Positive
TEM teams with Median to add FDA-cleared eyonis LCS to Pixel, boosting AI lung cancer screening and expanding its imaging portfolio.
Read More
Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
In preliminary, unaudited financial results, TEM posts 83% revenue growth and record data sales in 2025, but valuation and ongoing GAAP losses cloud the outlook before Q4 earnings.
Read More
TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
AI momentum is reshaping med-tech, with Tempus AI scaling diagnostics and Doximity leveraging platform-wide AI, strong margins, and cash flow to gain an edge.
Read More
Tempus Logix Launches AI-Powered Calculator to End Hidden Fees and Price Fluctuation in Auto Transport
Published: January 26, 2026 by: Newsfile Corp
Sentiment: Neutral
Tempus Logix Auto Transport launches an AI-powered calculator that delivers instant, exact car shipping prices with no hidden fees. Los Angeles, California--(Newsfile Corp. - January 26, 2026) - Tempus Logix Auto Transport has announced the launch of a new AI-driven instant car shipping calculator designed to bring unprecedented transparency and certainty to the vehicle transport process.
Read More
How TEM Is Capitalizing on AI-Driven Pathology Market Growth
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Tempus AI boosts AI pathology reach by acquiring Paige and launching Paige Predict to deliver biomarker insights across 16 cancer types.
Read More
Tempus AI: Staying Bullish On Leading Healthcare AI Play
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Tempus AI (TEM) remains a resilient healthcare AI leader, with proprietary data driving traction and a clear buy opportunity amid recent volatility. TEM reported preliminary 2025 revenue of ~$1.27B (+30% organic growth) and >$1.1B total contract value, supporting a robust multi-year growth runway. 2026 guidance calls for 25% revenue growth to $1.59B and adjusted EBITDA expansion to ~$65M, with management reinvesting two-thirds of incremental profit.
Read More
HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right now? Let's dive in.
Read More
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.
Read More
How Tempus AI Is Building Scale While Near-Term Risks Persist
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Negative
TEM is scaling via growing multi-quarter bookings, but delayed revenue conversion, MRD competition and rising losses keep near-term risks in focus.
Read More
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI and Hims & Hers are riding healthcare IT growth, but diagnostics scale and consumer demand set different upside paths.
Read More
Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI posts first positive adjusted EBITDA as genomics testing accelerates and data bookings broaden. Zacks Rank #3 (Hold) with mixed Style Scores.
Read More
Tempus AI: Plenty Of Growth Catalysts Ahead, Grab It While It's Down
Published: December 16, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI remains a Buy after a market-driven correction, with operational performance and partnerships strengthening the long-term thesis. TEM's organic revenue grew 28% y/y, gross margins improved 450bps to 63%, and liquidity increased to $760M, supporting continued investment and debt service. Management targets sustainable 25% annual genomics growth through 2028, with high-margin Data & Insights segment poised for outsized profitability.
Read More
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
Read More
3 MedTech Stocks Poised to Gain in 2026 From the AI Boom
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
AI is reshaping MedTech, and Stryker, Tempus AI and GE HealthCare are emerging as key players leveraging AI across surgery, diagnostics and imaging.
Read More
Tempus AI Near $75 Target? Valuation, Upside and Risks
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
Read More
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
Read More
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.
Read More
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
Read More
Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition.
Read More
Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?
Published: December 05, 2025 by: The Motley Fool
Sentiment: Positive
Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies.
Read More
Why Is Tempus (TEM) Down 8.9% Since Last Earnings Report?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Tempus (TEM) reported earnings 30 days ago. What's next for the stock?
Read More
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Read More
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET. The live webcast will be available through the events page of Tempus' Investor Relations website or by clicking the following link: https://ev.
Read More
About Tempus AI, Inc. (TEM)
- IPO Date 2024-06-14
- Website https://www.tempus.com
- Industry Medical - Healthcare Information Services
- CEO Eric Lefkofsky
- Employees 2400